NCT01812525View on ClinicalTrials.gov

Moderate to Severe Bronchiolitis: Standard Therapy Versus Therapy With NaCl 3% Inhalations

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Moderate to Severe Bronchiolitis
Interventions
DRUG

NaCl 3%

NaCl 3%: 4ml QID

OTHER

Standard therapy

Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed

Trial Locations (1)

1000

Hôpital de l'Enfance, Lausanne

All Listed Sponsors
collaborator

Swiss Foundation for the Health of Children and Adolescents

OTHER

lead

Raphaelle Jaquet-Pilloud

OTHER

NCT01812525 - Moderate to Severe Bronchiolitis: Standard Therapy Versus Therapy With NaCl 3% Inhalations | Biotech Hunter | Biotech Hunter